Navigation Links
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Date:9/2/2007

"intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

References:

1. Antman EM, Morrow DA, McCabe CH, et al; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477-1488.

2. Montalescot G, White HD, Gallo R, et al; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355:1006-1017.

3. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007 [e-pub ahead of print].


'/>"/>
SOURCE Sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... DUBLIN , June 02, 2015 /PRNewswire/ ... has announced the addition of the ... Testing Market" report to their offering. ... analysis of the US immunoprotein diagnostic market, ... market shares, and strategic profiles of leading ...
(Date:6/3/2015)... June 03, 2015 On April 21, 2015, ... Utilities and Communications Committee (11-0) and indicates the legislature's desire ... renewable energy. , The Committee Chairman supports the bill and ... CAP by 8,000 GWh and would also like to see ... , This “Wait List” and timing are extremely important. ...
(Date:6/3/2015)... June 3, 2015  HireLifeScience.com, the premier career ... host its 6 th annual career fair ... Raritan Center in Edison, NJ ... Novo Nordisk, Covance, Actavis and AstraZeneca.  Additional Pharmaceutical, ... exhibiting are Johnson & Johnson, MedImmune, DSM Nutritional ...
(Date:6/3/2015)... REYKJAVIK, Iceland , June 3, 2015   ... genome to improve health worldwide, today announced that it ... to provide clinical interpretation of the whole genome sequences ... of the first phase of the 100,000 Genomes Project ... WuXi NextCODE will deploy its unique database ...
Breaking Biology Technology:United States Strategies in the Immunoprotein Diagnostic Testing Market Report 2015 2Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in both Rare Disease and Cancer 2
... 7 Mylan Inc. (Nasdaq: MYL ) today ... from the U.S. Food and Drug Administration (FDA) for its ... , , Bicalutamide Tablets are the generic version of ... of approximately $322 million for the 12 months ending March ...
... ArborGen, LLC, a leader in forest ... ongoing field trials that are utilizing technology in-licensed from ... The two companies had previously announced that trees ... rates in 3-year-old field trials. , , ...
... , , Data published in July 7, ... Academy of Sciences, , , QUEBEC CITY, July 7 ... TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy ... journal, Proceedings of the National Academy of Sciences (PNAS), of ...
Cached Biology Technology:ArborGen and Senesco Announce Wood Quality Results 2ArborGen and Senesco Announce Wood Quality Results 3ArborGen and Senesco Announce Wood Quality Results 4AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 2AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 3AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 4
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... that normally suppress tumor growth. Now, for the first time, ... in mice can cause tumors to shrink or disappear. ... p53 is a promising target for human cancer drugs. ... in human tumors in which this pathway is blocked, they ...
... study in Nature (1) suggested that terrestrial plants may ... methane, making plants substantial contributors to the annual global ... triggered a consortium (2) of Dutch scientists to re-examine ... Tom Dueck and colleagues present their results and conclude ...
... researchers at Washington University School of Medicine in St. ... any coaxing. Then, because of the unusual meal, the ... injected into mice. , Developed in the laboratories ... Ph.D., the nanoparticles could soon allow researchers and physicians ...
Cached Biology News:Reactivated gene shrinks tumors 2Reactivated gene shrinks tumors 3Plants do not emit methane 2Nanoparticles can track cells deep within living organisms 2Nanoparticles can track cells deep within living organisms 3
... Rabbit polyclonal to MSY2/YBOX2 ( ... Antigen: Synthetic ... to the C-terminus of Human MSY2/YBOX2. ... is proprietary) (Peptide ...
Request Info...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: